摘要
目的 探讨立体定向放射(SRT )结合肝动脉化疗栓塞(TACE)治疗原发性肝癌的疗效。方法 对43例未行手术治疗的原发性肝癌患者,放射治疗前均行肝动脉化疗栓塞(TACE )治疗2～4次,SRT采用15MVX射线,肿瘤计划靶体积(PTV )≤12 5cm3 者单次剂量为5～6Gy ,生物等效剂量为DT5 6～60Gy ;PTV >12 5cm3 者单次剂量为4Gy ,生物等效剂量为5 0～5 6Gy ,放射治疗每天1次。结果 12例完全缓解(CR ) ,2 2例部分缓解(PR ) ,4例稳定(NR) ,5例进展(PD ) ,肿瘤总有效(CR +PR)率为79.1% (3 4/4 3 )。1、2、3年生存率分别为74.4% ,5 3 .5 % ,44 .2 % ,治疗前PTV≤12 5cm3 者治疗后的3年生存率(5 5 .2 % )高于PTV >12 5cm3 者(2 1.4% ) (χ2 =4.3 6,P <0 .0 5 )。结论 立体定向放射结合肝动脉化疗栓塞治疗原发性肝癌有较好的疗效。
Objective To evaluate the effect of stereotactic hypofractionated high-dose radiotherapy(SRT) combined with transarterial chemeombolization(TACE) for primary liver cancer.Methods 43 unresectable primary liver cancer,they were first treated with transarterial chemeobolization(TACE) for 2～4 sessions.For SRT,radiation was given by 15 MV X-ray.Patients whose plan target volume(PTV) was smaller than 125 cm3 received a biologically effective dose of 56～60 Gy,5～6 Gy per session everyday.Patients whose PTV was larger than 125 cm3 received a biologically effective dose of 50～56 Gy,4 Gy per session everyday.Results Twelve patients achieved CR,22PR,4NR and 5 PD,with a total response rate of 79.1%(34/43).The 1-,2-,3-year survival rates were 74.4.2%,53.5% and44.2%.The main factors affecting the prognosis in the SRT plus TACE were the size of tumor(55.2%:21.4%;χ2=4.36,P<0.05).Conclusion Stereotactic hypofractionated high-dose radiotherapy combined with TACE should be considered as an effective and feasible approach in the treatment of primary liver cancer patients.
出处
《实用癌症杂志》
2005年第1期87-89,共3页
The Practical Journal of Cancer
